Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD40 | P25942 | 1/20 | 0.49 |
| ▸ | CD40LG | P29965 | 1/20 | 0.49 |
| ▸ | PRMT1 | Q99873 | 3/20 | 0.48 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.48 |
| ▸ | EP300 | Q09472 | 1/20 | 0.48 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.48 |
| ▸ | ENPP2 | Q13822 | 9/20 | 0.47 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.35 |
| ▸ | CASP6 | P55212 | 1/20 | 0.34 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA3 | P07451 | 1/20 | 0.32 |
| ▸ | PHLPP2 | Q6ZVD8 | 1/20 | 0.32 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13046146 | 0.78 | PRMT1 (0.79) | CD40CD40LGPRMT1PRMT3EP300 | |
| SCHEMBL12975927 | 0.78 | CD40 (0.56) | CD40CD40LGPRMT1PRMT3EP300 | |
| SCHEMBL13845525 | 0.78 | ENPP2 (0.68) | CD40CD40LGPRMT1PRMT3EP300 | |
| SCHEMBL13995000 | 0.75 | PRMT3 (0.55) | CD40CD40LGPRMT1PRMT3EP300 | |
| SCHEMBL14370961 | 0.73 | CD40 (0.69) | CD40CD40LGPRMT1PRMT3EP300 | |
| SCHEMBL13715874 | 0.70 | PRMT1 (0.44) | CD40CD40LGPRMT1PRMT3EP300 | |
| SCHEMBL6078254 | 0.70 | PRMT1 (0.58) | CD40CD40LGPRMT1PRMT3EP300 | |
| SCHEMBL14578748 | 0.69 | PRMT1 (0.41) | CD40CD40LGPRMT1PRMT3EP300 | |
| SCHEMBL13845510 | 0.69 | ENPP2 (0.57) | CD40CD40LGPRMT1PRMT3EP300 | |
| SCHEMBL6079026 | 0.69 | PRMT1 (0.60) | CD40CD40LGPRMT1PRMT3EP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531009-B2 | 6-azo-5,5′-dihydroxy-7,7′-disulfo-2-2′ dinaphthylamine derivatives | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2009-05-12 | — | — | US | disclosed |
| US-20080196180-A1 | 6-Azo-5,5'-Dihydroxy-7,7'-Disulfo-2-2' Dinaphthylamine Derivatives | CIBA SPECIALTY CHEMICALS CORP. | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080196180-A1 | 6-Azo-5,5'-Dihydroxy-7,7'-Disulfo-2-2' Dinaphthylamine Derivatives | H1-5, DHODH, DDT | CD40 4510/4885CD40LG 3210/4885PRMT1 2442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.